XML 21 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jan. 03, 2025
Dec. 29, 2023
Current assets:    
Cash and cash equivalents $ 217,374 $ 262,994
Marketable securities 893,902 732,308
Trade receivables, net 265,437 237,407
Inventory 22,388 17,323
Prepaid expenses and other current assets 68,478 67,926
Total current assets 1,467,579 1,317,958
Non-current marketable securities 637,291 728,717
Property and equipment, net 119,391 128,731
Deferred tax assets, net 420,027 361,145
Goodwill 63,684 63,684
Right-of-use assets and other non-current assets 239,718 342,122
Total assets 2,947,690 2,942,357
Current liabilities:    
Accounts payable 38,191 33,768
Accrued compensation and benefits 109,830 93,325
Accrued clinical trial liabilities 57,976 71,615
Rebates and fees due to customers 62,376 59,619
Accrued collaboration liabilities 40,384 27,533
Other current liabilities 95,012 108,417
Total current liabilities 403,769 394,277
Non-current operating lease liabilities 190,823 189,944
Other non-current liabilities 108,895 94,224
Total liabilities 703,487 678,445
Commitments and contingencies (Note 12)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 281,732 and 302,793 at December 31, 2024 and 2023, respectively 282 303
Additional paid-in-capital 2,343,915 2,440,710
Accumulated other comprehensive loss (1,347) (3,750)
Accumulated deficit (98,647) (173,351)
Total stockholders’ equity 2,244,203 2,263,912
Total liabilities and stockholders’ equity $ 2,947,690 $ 2,942,357